A new study published in JAMA Pediatrics reveals that gender-affirming medications, such as puberty blockers and hormone treatments, are significantly less common among U.S. adolescents than critics suggest. The study analyzed insurance claims data for over 5 million adolescents and found that fewer than 1 in 1,000 received these treatments between 2018 and 2022. The findings contradict claims of widespread access to such care and come amidst political debates and legal challenges surrounding transgender healthcare.
As debates over transgender healthcare intensify across the United States, a new study offers clarity, revealing that gender-affirming medications are far less common than critics claim. Published Monday in JAMA Pediatrics, the study found that fewer than 1 in 1,000 U.S. adolescents received puberty blockers or hormone treatments between 2018 and 2022.The researchers analyzed a database of insurance claims for over 5 million adolescents aged 8 to 17 with commercial insurance plans.
The U.S. Supreme Court is expected to rule on the issue later this year, with implications for similar cases nationwide.President-elect Donald Trump has pledged to roll back protections for transgender people, further politicizing the topic.Medical professionals argue that gender-affirming care is applied cautiously, guided by individual needs and expert oversight. Dr.
Transgender Healthcare Puberty Blockers Hormone Therapy Adolescents Medical Care
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
US Study Finds Low Rate of Gender-Affirming Care for Transgender YouthA new study published in JAMA Pediatrics reveals that the rate of gender-affirming medical care for transgender youth is significantly lower than previously thought.
Read more »
Few US Teens with Private Insurance Receive Gender-Affirming Care, Study FindsA new study reveals that less than 0.1% of teenagers with private insurance in the US who have been diagnosed with gender dysphoria are receiving puberty blockers or cross-sex hormones. The findings shed light on the impact of recent state bans on gender-affirming care.
Read more »
Few US Youth Seek Gender-Affirming Care, Study FindsA new study analyzing private insurance claims data reveals that less than 0.1% of US youth accessed puberty blockers or hormones for gender transition.
Read more »
'A very, very small number' of teens receive gender-affirming care, study findsA new analysis of private insurance claims data finds less than 0.1% of youth accessed puberty blockers or hormones for gender transition. This small group has garnered a huge amount of attention from Republican lawmakers in recent years.
Read more »
Study: Less Than 0.1% of Youth Access Gender-Affirming CareA new analysis of private insurance claims data reveals that less than 0.1% of youth in the U.S. received puberty blockers or hormones for gender transition. This finding challenges the narrative surrounding transgender youth that has garnered significant attention from Republican lawmakers, who have implemented bans on gender-affirming care in numerous states.
Read more »
Rarely Prescribed: Study Finds Few Transgender Youth Receive Gender-Affirming CareA new study published in JAMA Pediatrics reveals that access to gender-affirming care, including puberty blockers and hormones, for transgender youth is limited.
Read more »